Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
View Scopus Profile
Xin Guo
Research Associate
School of Medicine
1995 …
2024
Research activity per year
Overview
Fingerprint
Network
Research output
(29)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Xin Guo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Dendritic Growth
100%
Sympathetic Neurons
85%
Bone Morphogenetic protein-7 (BMP-7)
44%
Bone Morphogenetic Protein
37%
Osteogenic Proteins
36%
Dendrite
28%
Axonal Growth
25%
Glia
22%
Proteasome Activity
18%
Morphological Differentiation
18%
Bone Morphogenetic Protein Antagonist
18%
Extracellular Matrix Protein 1 (ECM1)
18%
Transcriptional Response
18%
Smad1
18%
GTPase
18%
Synphilin-1
18%
Alpha-particle Emitters
18%
Alpha-synuclein (α-syn)
18%
Neuroimmunophilin
18%
Neuroprotective
18%
Proof of Concept Study
18%
Osteosarcoma
18%
Anti-GD2
18%
Therapeutic Efficacy
18%
Neuroregenerative
18%
Humanized Antibody
18%
FK506-binding Protein
18%
Polymeric Nanoparticles
18%
Gene Delivery
18%
Endometrial Cancer
18%
Adrenergic Signaling Pathway
18%
Cross-regulation
18%
Reactive Oxygen Species
18%
PAX8
18%
Dual-target
18%
Alpha-fetoprotein
18%
Non-invasive Ultrasound
18%
ErbB2
18%
Orthotopic Osteosarcoma
18%
Tumor Suppressor
18%
ARID1A
18%
Ultrasound Examination
18%
Doxorubicin-induced Cardiotoxicity
18%
Pten
18%
Overexpression
18%
Basal Level
18%
Antioxidant Enzymes
18%
Ultrasound
18%
Cancer Progression
18%
Targeted Theranostics
18%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
39%
Osteosarcoma
36%
Neoplasm
31%
Mouse
26%
Mouse Model
21%
Tumor Growth
21%
Nanoparticle
20%
Lung Metastasis
20%
Combination Therapy
20%
Iron Oxide Nanoparticle
18%
Gene Delivery
18%
Technetium 99m
18%
Reactive Oxygen Metabolite
18%
Syndrome
18%
Antioxidant
18%
Human Serum Albumin
18%
Cancer Model
18%
Prostate Cancer
18%
Doxorubicin
18%
Prostate Specific Membrane Antigen
18%
Antibody Drug Conjugate
18%
Rat Model
18%
Liver Cell Carcinoma
18%
Prenatal Stress
18%
Sprague Dawley Rat
18%
Spermidine
18%
Cardiotoxicity
18%
Trastuzumab
16%
Malignant Neoplasm
16%
Deferoxamine
13%
Zirconium 89
13%
Alpha Fetoprotein
12%
Overall Survival
11%
Functional Groups
9%
Epidermal Growth Factor Receptor 2
6%
Actinium 225
6%
Spermine
6%
Metastatic Breast Cancer
5%
Toll Like Receptor
5%
Medicine and Dentistry
Neoplasm
21%
Spermidine
18%
Endometrial Cancer
18%
Tumor Suppressor Protein
18%
Fk 506 Binding Protein
18%
Cell Cycle
18%
Positron Emission Tomography
18%
Cancer Model
18%
Prenatal Stress
18%
Single-Photon Emission Computed Tomography
18%
Osteosarcoma
18%
Lung Tumor
18%
Combination Therapy
18%
Breast Cancer
18%
Teprenone
18%
Human Serum Albumin
18%
Cancer Growth
18%
Hepatocellular Carcinoma
18%
Technetium-99
18%
Nanoparticle
18%
Gene Targeting
18%
Xenograft
18%
Malignant Neoplasm
16%
Deferoxamine
13%
Trastuzumab
13%
Zirconium 89
13%
Spermine
12%
Growth Factor Receptor
12%
Alpha-Fetoprotein
12%
Polyamine
9%
Gross Pathology
9%
Functional Groups
9%
Uterus Disease
9%
Morphology
9%
Treatment Response
9%
Ultrasound Technology
9%
Ovary Follicle Maturation
9%
Echography
9%
Disease
9%
Particle Therapy
9%
Uterine Cancer
9%
Mertansine
7%
Targeted Therapy
6%
Genetic Transfection
6%
Carcinoma Cell
6%
Actinium 225
6%
Overall Survival
6%
Child
6%
Metastatic Carcinoma
6%
